NRX Pharmaceuticals, Inc. (NRXP): Results of Operations and Financial Condition
NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17 th at 4:30pm ET Key recent and second quarter highlights include: ● Completed first-cycle FDA review of the
How this was made
The 30-second read
Why it matters
The filing itself is a procedural disclosure that the earnings press release exists; the trading-relevant impact depends on the specific Q2 financials and any guidance or operational updates contained in Exhibit 99.1, which are not included in the provided text.
Market read
Traders should treat this as an earnings-release trigger for NRXP, but the provided scrape does not contain the numbers needed to form a directional view.
What to watch
Traders should verify whether Exhibit 99.1 includes material items such as cash burn, runway, R&D milestones, or any updated clinical/regulatory timelines, which are not present here.
NRx Pharmaceuticals reports second-quarter 2026 results, advances preservative-free ketamine toward commercialization, and says current cash resources are sufficient for at least one year of operations.
The filing highlights progress toward preservative-free ketamine commercialization and a substantially larger cash balance, but reports no quarterly revenue, revenue growth, EPS, operating cash flow, or free cash flow. For the six months ended June 30, 2026, net loss improved while net operating loss increased.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net loss for the six months ended June 30GAAP | $18.0 million | – | – |
| Net operating loss for the six months ended June 30GAAP | $11.3 million | – | – |
| Cash and cash equivalentsother | approximately $26.7 million | – | – |
| Gross proceeds from underwritten public offering of common stockother | $22.3 million | – | – |
2026 and 2027 outlook
- NoteThe Company aims for 2026 approval and commercialization of preservative-free ketamine.
- NoteFive million units of launch stock is currently in the manufacturing process with anticipated post launch manufacture of 1 million units per month.
- NoteAnticipated non-dilutive funding exceeds $11.5 million, subject to completion of contracting.
- NoteManagement believes current cash resources, anticipated growth in clinic revenue, and opportunistic utilization of the Company's active at-the-market offering facility will be sufficient to support operations for at least one year.
- NoteThe Company is now poised to finalize its NDA, aiming for 2027 approval.
- NoteGNK-301’s first-in-human trial is targeted for July 2027.
What drove it
- The FDA completed first-cycle review of the Company’s ANDA for preservative-free ketamine with no drug-related major deficiencies.
- The sole remaining ANDA item described by the Company was a manufacturer’s attestation on the vial, which has been submitted to the FDA.
- Commercial-scale manufacturing of preservative-free ketamine has started to build launch stock.
- DARPA selected NRx as prime contractor for the SPARC-TMS trial of NRX-101 with robotic TMS.
- HOPE Therapeutics added sites in Sarasota and Boca Raton, Florida, and became the first commercial site in the US to treat patients using Zeta Surgical’s FDA-cleared TMS navigation system.
- The company appointed Glenn Tyson as its first Chief Commercial Officer and retained a commercial launch team for preservative-free ketamine.
Concerns
- The filing reports no standalone second-quarter revenue, revenue growth, gross margin, operating income, net income, EPS, operating cash flow, or free cash flow.
- For the six months ended June 30, 2026, net operating loss was $11.3 million versus $7.6 million for the comparable period in 2025.
- The company attributed the higher six-month operating loss to research and development costs related to acquired assets and increased selling, general and administrative costs tied to personnel and anticipated commercial launch activities.
- The anticipated DARPA funding exceeds $11.5 million but is subject to completion of contracting.
- The company states that it has reported regulatory milestones achieved but has not predicted the outcome of any future regulatory determination.
What to watch
- FDA disposition of the submitted manufacturer’s attestation related to the luer lock component of the preservative-free ketamine vial.
- Progress toward the company’s stated 2026 approval and commercialization objective for preservative-free ketamine.
- Completion of contracting for anticipated DARPA funding exceeding $11.5 million.
- Commercial-scale manufacturing progress toward five million units of launch stock and anticipated post-launch manufacture of 1 million units per month.
- Finalization and regulatory progress of the NRX-100 NDA, for which the company is aiming for 2027 approval.
- Growth in HOPE Therapeutics clinic revenue, which management cited as part of its expected funding of operations for at least one year.
Balance sheet and cash flow
- As of June 30, 2026, the Company had approximately $26.7 million in cash and cash equivalents versus $7.8 million as of December 31, 2025.
- The increase was primarily related to the Company’s completion of a public offering of common stock with gross proceeds of more than $22 million.
- Closed an institutionally-supported, underwritten public offering of common stock for gross proceeds of $22.3 million, including full exercise of the underwriters’ option.
Analysis
NRx’s reported financial disclosure is limited to six-month loss figures and balance-sheet cash, rather than a complete standalone second-quarter income statement. Net loss for the six months ended June 30, 2026 was $18.0 million, versus $23.1 million during the comparable 2025 period. The company attributed the change primarily to fair-value accounting measurements and other non-recurring charges associated with conversion and restructuring of previously issued convertible notes in the 2025 period. At the same time, net operating loss increased to $11.3 million from $7.6 million, driven by research and development costs related to acquired assets and higher selling, general and administrative costs, including commercial-launch preparation.
Liquidity was the central financial positive in the release. Cash and cash equivalents were approximately $26.7 million as of June 30, 2026, compared with $7.8 million as of December 31, 2025. The company linked the increase principally to its public common-stock offering, described as generating $22.3 million of gross proceeds. Management stated that current cash resources, anticipated clinic-revenue growth, and opportunistic use of its active at-the-market facility would support operations for at least one year.
Operationally, the main near-term event is the preservative-free ketamine ANDA. The company said FDA identified no major deficiencies related to the drug or its manufacture, while identifying a single major deficiency concerning a manufacturer’s attestation for the vial’s luer lock component. NRx said it submitted that attestation and is building five million units of launch stock, with anticipated post-launch manufacture of 1 million units per month. The company aims for 2026 approval and commercialization, but the release also states that it has not predicted the outcome of future regulatory determinations.
The company also outlined pipeline and commercial-network activity. DARPA selected NRx as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS, with anticipated non-dilutive funding exceeding $11.5 million subject to contracting. NRx is also advancing the NRX-100 NDA using Real World Evidence from more than 65,000 patients and is aiming for 2027 approval. HOPE Therapeutics expanded into Sarasota and Boca Raton and began treating patients with Zeta Surgical’s FDA-cleared TMS navigation system.
The release contains no reported revenue, segment revenue, gross margin, EPS, operating cash flow, free cash flow, debt balance, or prior-quarter financial line items. As a result, the financial read depends principally on the cash increase, the six-month loss trends, and execution against regulatory, manufacturing, contracting, and clinic-growth objectives. There was no prior outlook supplied for comparison, and the filing does not provide a basis to assess performance against prior guidance.
Management, verbatim
The second quarter of 2026 was a major inflection point for NRx as we advance our mission to bring hope to the most vulnerable patients battling depression and suicidal ideation.
Dr. Jonathan Javitt, CEO and Chairman
We have continued to drive towards our key objective of first commercial ketamine sales in 2026 with corresponding manufacturing operations and build-out of our first commercial team.
Dr. Jonathan Javitt, CEO and Chairman
Not in the filing
stated, not guessed- Standalone second-quarter 2026 total revenue
- Prior-year and prior-quarter total revenue comparisons
- Revenue growth rates
- Segment revenue and segment revenue growth
- Gross profit and gross margin
- Operating income or loss for the standalone second quarter
- Net income or loss for the standalone second quarter
- GAAP EPS
- Non-GAAP EPS
- Non-GAAP financial metrics and reconciliations
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases
- Dividend payments
- Revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Previous-quarter outlook or guidance for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The SEC 8-K (Item 2.02) states NRX Pharmaceuticals announced its second-quarter 2026 results for the quarter ended June 30, 2026 and furnished the press release as Exhibit 99.1.
Ticker impact
NRX Pharmaceuticals filed an 8-K stating it announced Q2 2026 results for the quarter ended June 30, 2026 via Exhibit 99.1.
Near-term volatility possible on the actual Q2 numbers once traders read Exhibit 99.1, but direction cannot be inferred from the provided text.
The body only confirms the existence of a Q2 results press release furnished as Exhibit 99.1, without reporting any figures, outlook, or operational updates.
Market effects
Limited from the provided text because no drug pipeline, trial, or guidance specifics are disclosed.
None indicated.
None indicated.
Counterpoint
Because the scraped content omits the actual Q2 results, the market reaction may be driven by details in Exhibit 99.1 rather than the mere filing.
Key entities
- issuerNRX Pharmaceuticals, Inc.
Company filing Form 8-K for Q2 2026 results (Item 2.02) and furnishing Exhibit 99.1 press release.
- documentExhibit 99.1
Press release dated August 17, 2026 containing the actual Q2 results details.
